Intratympanic corticosteroids for Ménière’s disease-Reference-Cited by-同舟云学术

Intratympanic corticosteroids for Ménière’s disease

Published:2023-02-27 Issue:2 Volume:2023 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Webster Katie E¹,Lee Ambrose²,Galbraith Kevin³,Harrington-Benton Natasha A⁴,Judd Owen⁵,Kaski Diego⁶,Maarsingh Otto R⁷,MacKeith Samuel⁸,Ray Jaydip⁹,Van Vugt Vincent A⁷,Westerberg Brian¹⁰,Burton Martin J¹¹

Affiliation:

1. Cochrane ENT, Nuffield Department of Surgical Sciences; University of Oxford; Oxford UK

2. Department of Otolaryngology - Head and Neck Surgery; University of Toronto; Toronto Canada

3. Cochrane ENT; Nuffield Department of Surgical Sciences, University of Oxford; Oxford UK

4. Ménière’s Society; Wooton UK

5. ENT Department; University Hospitals of Derby and Burton NHS Foundation Trust; Derby UK

6. National Hospital for Neurology and Neurosurgery; London UK

7. Department of General Practice, Amsterdam UMC; Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute; Amsterdam Netherlands

8. ENT Department; Oxford University Hospitals NHS Foundation Trust; Oxford UK

9. University of Sheffield; Sheffield UK

10. Otology & Neurotology; St. Paul's Rotary Hearing Clinic; Vancouver Canada

11. Cochrane UK; Oxford UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference91 articles.

1. OTO-104 in Meniere's disease patients: phase 3 results;Lambert;Otolaryngology - Head and Neck Surgery,2017

2. A prospective, randomized, double-blind, placebo-controlled, multicenter, phase 3 study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere's disease (NCT02612337) https://clinicaltrials.gov/ct2/show/NCT02612337

3. Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease https://investors.otonomy.com/news-releases/news-release-details/otonomy-reports-results-averts-1-phase-3-trial-otividextm

4. A prospective, randomized, double-blind, placebo-controlled, multicentre, phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Ménière's disease https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004496-71 2021

5. AVERTS-2 phase 3 results of Otividex in Meniere disease;Phillips;Otolaryngology - Head and Neck Surgery,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of prior intratympanic gentamicin and corticosteroids therapy on speech understanding in patients with Menière's disease after cochlear implantation;European Archives of Oto-Rhino-Laryngology;2024-02-02

2. Stratification of patients with Menière’s disease based on eye movement videos recorded from the beginning of vertigo attacks and contrast-enhanced MRI findings;Frontiers in Neurology;2024-01-11

3. Efficacy and preservation of hearing with low-dose gentamicin in unilateral meniere's disease: A clinical symptomatology-based study;American Journal of Otolaryngology;2024-01

4. Schwindel;Therapie-Handbuch - Neurologie;2024

5. Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans—a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST);Frontiers in Neurology;2023-10-18